From: Cancer immunotherapy: the beginning of the end of cancer?
Agents | Indication | Regimen or design | n | Overall response (CR and PR) | Survival | Refs |
---|---|---|---|---|---|---|
Ipilimumab and nivolumab | Advanced-stage untreated melanoma | Nivolumab or ipilimumab alone versus nivolumab plus ipilimumab | 945 | -44 % nivolumab -19 % ipilimumab -58 % ipilimumab plus nivolumab | Median PFS: -2.9 months for ipilimumab* -6.9 months for nivolumab†-11.5 months for nivolumab plus ipilimumab*,†| [98] |
Ipilimumab and nivolumab | Advanced-stage melanoma | Concurrent or sequential combination with dose escalation | 53 | 42Â % (concurrent combination) | OS rate: -85Â % 1-year -79Â % 2-year | [146] |
Ipilimumab and nivolumab | Advanced-stage untreated melanoma | Ipilimumab alone versus Ipilimumab plus nivolumab | 142 | -11Â % ipilimumab* -61Â % ipilimumab plus nivolumab* | Median PFS: -4.4Â months for ipilimumab -Not reached for ipilimumab plus nivolumab | [147] |
Ipilimumab and GP100 vaccine | Previously treated advanced-stage melanoma | Ipilimumab or vaccine alone versus ipilimumab plus vaccine | 676 | -10.9 % ipilimumab alone* -1.5 % vaccine alone†-5.7 % ipilimumab with vaccine*,†| Median OS: -10.1 months for ipilimumab alone -6.4 months for vaccine alone* -10.0 months for ipilimumab plus vaccine* | [13] |
Ipilimumab and dacarbazine | Advanced-stage untreated melanoma | Dacarbazine alone versus Ipilimumab plus dacarbazine | 502 | -10.3Â % dacarbazine alone -15.2Â % ipilimumab with dacarbazine | Median OS: -9.1Â months for dacarbazine alone* -11.2Â months for ipilimumab plus dacarbazine* | [79] |
Ipilimumab and radiotherapy | Post-docetaxel CRPC | Radiotherapy followed by placebo versus radiotherapy followed by ipilimumab | 799 | NA | Median OS: -10.0Â months for radiotherapy followed by placebo -11.2Â months for radiotherapy followed by ipilimumab | [149] |
Carboplatin plus paclitaxel with placebo or ipilimumab | NSCLC | Placebo control versus phased or concurrent schedule | 204 | -18Â % chemotherapy control -32Â % irBORR ipilimumab | Median irPFS: -4.6Â months chemotherapy control* -5.7Â months for phased ipilimumab* | [150] |
Carboplatin plus paclitaxel with placebo or ipilimumab | ED-SCLC | Placebo control versus phased or concurrent schedule | 130 | -53Â % chemotherapy control -71Â % irBORR ipilimumab | Median irPFS: -5.3Â months chemotherapy control* -6.4Â months for phased ipilimumab* | [151] |